For an adult with anxiety and trauma undergoing EMDR, is cannabis appropriate and what dosing, THC/CBD limits, and safety considerations should be followed?

Cannabis Use During EMDR Therapy for Trauma and Anxiety: Clinical Recommendations

Cannabis, particularly THC-predominant products, should generally be avoided or minimized during EMDR and trauma-focused therapy for PTSD and anxiety, as evidence shows trauma-focused treatments like EMDR are effective regardless of cannabis use, while cannabis itself carries substantial mental health risks without proven therapeutic benefit for these conditions.

Evidence-Based Treatment Approach

Trauma-Focused Therapy Remains First-Line

• EMDR and other trauma-focused therapies (including prolonged exposure and cognitive restructuring) are the evidence-based treatments for PTSD and trauma, not cannabis. 1
• Current PTSD treatment guidelines recommend trauma-focused interventions without requiring a prolonged stabilization phase, even for complex PTSD presentations. 1
• Trauma-focused treatment demonstrates efficacy regardless of baseline cannabis use, with participants achieving similar reductions in PTSD symptoms whether or not they report cannabis consumption. 2

Cannabis Lacks Evidence for Mental Health Benefits

• There is low-certainty evidence that THC-predominant cannabis may NOT improve PTSD symptoms, and largely insufficient evidence to characterize effects on anxiety disorders. 3
• No cannabis-based finished product has been approved for treatment of any mental illness, including PTSD or anxiety disorders. 4
• The current evidence base is not sufficient to support cannabis use for treatment of mental health conditions and demonstrates substantial risks of adverse effects. 3

Safety Concerns and Contraindications

High-Risk Populations Should Avoid Cannabis

• Cannabis use should be avoided in individuals at elevated risk of harms, including those with mood disorders (where it increases self-harm risk), bipolar disorder (worsening mania), psychotic spectrum disorders (increased psychotic symptoms), and those at risk for substance use disorders. 3
• Among people with past-year cannabis use, approximately 3 in 10 develop cannabis use disorder (CUD), with about half having moderate or severe disease with negative social and employment outcomes. 3
• Regular use of high THC-content products is associated with 2-fold to 11-fold increased risk of psychosis, higher risk of CUD, and self-harm in those with mood disorders. 3

Neurological and Cognitive Effects

• THC causes memory impairment, paranoid symptoms, and other cognitive effects that could theoretically interfere with the memory processing required during EMDR therapy. 5
• Cannabis affects neural circuitry involved in fear regulation, though the clinical significance during active trauma therapy remains unclear. 6

If Cannabis Use Continues: Harm Reduction Approach

Product Selection and Dosing Limits

If a patient insists on continuing cannabis during EMDR therapy, the following harm reduction strategies apply:

• Prefer CBD-dominant products (CBD:THC ratio >10:1) over THC-dominant formulations. 5
• Products with CBD:THC ratio <10:1 or balanced 1:1 products should be considered THC-dominant and carry higher risk. 5
• THC total daily dose-equivalent should generally be limited to 30 mg/day or less to avoid psychoactive sequelae and development of tolerance. 7

Starting and Titration Protocol

• Starting dose for THC-containing products should be low: 1-2.5 mg THC/day. 4
• Dose should be up-titrated slowly by 1-2.5 mg every 3-5 days. 4
• Average daily dose in clinical practice is 10-20 mg THC. 4
• CBD, when used, typically requires much higher doses (>400 mg/day) for potential anxiolytic effects. 4, 7

Monitoring Requirements

• Assess for worsening anxiety, emergence of psychotic symptoms, development of cannabis use disorder, and interference with trauma processing. 3
• Monitor for common adverse events including insomnia and fatigue (most frequent), which occurred in 20% of patients in registry data. 8
• Most adverse events are mild to moderate in severity. 8

Clinical Pitfalls to Avoid

Common Misconceptions

• Many patients self-medicate with cannabis believing it improves mental health symptoms, but this belief is not supported by current evidence. 3, 6
• Patients often report using cannabis to improve mood, sleep, and anxiety, yet conclusive scientific evidence of therapeutic properties is limited. 4, 6
• The lack of FDA regulation and standardization makes medical cannabis particularly problematic for psychiatric conditions. 6

Treatment Interference Concerns

• Do not delay or avoid trauma-focused therapy like EMDR based on cannabis use alone—the evidence shows trauma-focused treatments work regardless of cannabis use status. 2
• Cannabis use should not be considered a contraindication to initiating EMDR, but patients should be counseled about lack of benefit and potential risks. 3, 2
• Attendance rates may be lower in trauma-focused treatments, but PTSD symptom reductions are larger compared to non-trauma-focused approaches, regardless of cannabis use. 2

Preoperative Context (If Applicable)

For patients undergoing procedures requiring anesthesia:

• Cannabis consumption >1.5 g/day smoked, >300 mg/day CBD oil, or >20 mg/day THC oil requires specific perioperative planning. 5
• If surgery is <1 day away, do not wean or stop cannabis; if >7 days away, consider weaning or stopping. 5
• Additional anesthetic may be needed to ensure adequate depth of anesthesia in regular cannabis users. 5